Cancer Letters
Volume 125, Issue 1 , Pages 25-30 , 13 March 1998

Epstein–Barr virus infection and response to radiotherapy in squamous cell carcinoma of the oral cavity

Received 17 September 1997 ,Accepted 27 October 1997.

References 

  1. Zur-Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, et al. Epstein–Barr virus DNA in biopsies of Burkitt tumors and anaplastic carcinoma of the nasopharynx. Nature. 1970;228:1056–1058
  2. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein–Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet. 1991;337:320–322
  3. Patton DF, Ribeiro RC, Jenkins JJ, Sixbey JW. Thymic carcinoma with a defective Epstein–Barr virus encoding the BZLF1 trans activator. J. Infect. Dis. 1994;170:7–12
  4. Shibata D, Weiss LM. Epstein–Barr virus-associated gastric carcinoma. Am. J. Pathol. 1992;140:769–774
  5. Hamilton-Dutoit SJ, Therkildsen MH, Nielsen NH, Jensen H, Hansen JPH, Pallesen G. Undifferentiated carcinoma of the salivary gland in Greenland Eskimos: demonstration of Epstein–Barr virus DNA by in situ nucleic acid hybridization. Hum. Pathol. 1991;22:811–815
  6. Horiuchi K, Mishima K, Ichijima K, Sugimura M, Ishida T, Kirita T. Epstein–Barr virus in the proliferative diseases of squamous epithelium in the oral cavity. Oral Surg. Oral Med. Oral Pathol. 1995;79:57–63
  7. Fries KL, Miller WE, Raab TN. Epstein–Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol. 1996;70:8653–8659
  8. Okan I, Wang Y, Chen F, Hu FL, Imreh S, Klein G, et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not grown arrest. Oncogene. 1995;11:1027–1031
  9. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bcl-2 expression by Epstein–Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107–1115
  10. Goeltz SE, Hamilton SR, Vogelstein B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem. Biophys. Res. Commun. 1985;130:118–126
  11. Imai S, Usui N, Sugiura N, Osato T, Sato T, Tsutsumi H, et al. Epstein–Barr virus genomic sequences and specific antibodies in cerebrospinal fluid in children with neurologic complications of acute and reactivated EBV infections. J. Med. Virol. 1993;40:278–284
  12. Saiki RK, Gelfand JH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487–491
  13. Miller AB, Hoogstraten B, Statquet J. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  14. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457–481
  15. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013–2023
  16. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967
  17. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847–849
  18. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status efficacy of cancer therapy in vivo. Science. 1994;266:807–810
  19. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cell is associated with poor response to chemotherapy. Blood. 1993;81:3091–3096
  20. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–336
  21. Szekely L, Selivanova G, Magunusson KP, Klein G, Wiman KG. EBNA-5, an Epstein–Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA. 1993;90:5455–5459
  22. Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein–Barr virus latency. Mol. Cell. Biol. 1994;14:1929–1938
  23. Wong KY, Collins RJ, Srivastava G, Pittaluga S, Cheung AN, Wong LC. Epstein–Barr virus in carcinoma of the cervix. Int. J. Gynecol. Pathol. 1993;12:224–227
  24. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller LN, et al. Epstein–Barr virus latent membrane protein expression in Hodgkin and Reed–Sternberg cells. Proc. Natl. Acad. Sci. USA. 1991;88:4766–4770
  25. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, et al. Epstein–Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 1988;69:1051–1065
  26. Kanavaros P, Jiwa M, van der Valk P, Walboomers J, Horstman A, Meijer CJLM. Expression of Epstein–Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency. Hum. Pathol. 1993;24:725–729
  27. Fahraeus R, Rymo L, Rhim JS, Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein–Barr virus. Nature. 1990;345:447–449
  28. Naher H, Gissmann L, von Knebel Doeberitz C, von Knebel Doeberitz M, Greenspan JS, Greenspan D, et al. Detection of Epstein–Barr virus-DNA in tongue epithelium of human immunodeficiency virus-infected patients. J. Invest. Dermatol. 1991;97:421–424

PII: S0304-3835(97)00485-0

Cancer Letters
Volume 125, Issue 1 , Pages 25-30 , 13 March 1998

Article Tools

* Image Usage & Resolution